<DOC>
	<DOCNO>NCT01185405</DOCNO>
	<brief_summary>Voriconazole , new triazole-derivative , become drug choice many invasive fungal infection , include invasive Aspergillosis . Recently , therapeutic drug monitoring voriconazole issue wide variation unpredictability voriconazole blood concentration . The objective study 1 ) characterize pharmacokinetics voriconazole ICU patient voriconazole prophylaxis treatment , 2 ) develop evaluate prediction adjustment model voriconazole plasma level .</brief_summary>
	<brief_title>Voriconazole Plasma Level Intensive Care Unit ( ICU ) Patients</brief_title>
	<detailed_description>Patients randomly assign 2 group : conventional adjustment group ( CA group ) early adjustment group ( EA group ) . Voriconazole plasma level measure day 1 ( peak trough level ) , day 3 , day 5 , day 10 , day 14 ( trough level ) . For CA group patient , voriconazole dosage adjust accord trough level day 5 ( steady-state level ) . Predefined dose adjustment protocol use ( &lt; 1 µg/ml : 50 % increase , 1~5.5 µg/ml : change , &gt; 5.5 µg/ml : 50 % decrease ) . For EA group patient , voriconazole dosage adjust accord measurement voriconazole level day 1 . Adjusted dosage calculate use NONMEN software . The target range trough level 1.0 µg/ml 5.5 µg/ml . The appropriateness voriconazole level ( day 5 , day 10 , day 14 ) , mortality , ICU stay , frequency voriconazole-related adverse event compare . CYP2C19 polymorphism analyze patient .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients receive voriconazole Patients allergic azole ( )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Therapeutic drug monitoring</keyword>
	<keyword>Intensive care unit</keyword>
</DOC>